派姆单抗治疗膀胱癌致过敏性支气管肺真菌病1例

IF 0.7 Q4 RESPIRATORY SYSTEM

Respiratory Medicine Case Reports Pub Date : 2025-01-01 DOI:10.1016/j.rmcr.2025.102179

Hiroki Iida , Kenichiro Atsumi , Naohiro Kadoma , Sae Takashima , Yukari Shirakura , Ayana Suzuki , Kakeru Hisakane , Ryo Matsuoka , Koji Nagata , Masahiro Seike , Takashi Hirose

{"title":"派姆单抗治疗膀胱癌致过敏性支气管肺真菌病1例","authors":"Hiroki Iida , Kenichiro Atsumi , Naohiro Kadoma , Sae Takashima , Yukari Shirakura , Ayana Suzuki , Kakeru Hisakane , Ryo Matsuoka , Koji Nagata , Masahiro Seike , Takashi Hirose","doi":"10.1016/j.rmcr.2025.102179","DOIUrl":null,"url":null,"abstract":"<div><div>Pembrolizumab is an immune checkpoint inhibitor (ICI) of programmed cell death-1 category, used for treating various types of cancer. ICIs can sometimes result in immune-related adverse events. Allergic bronchopulmonary mycosis (ABPM) induced by ICI has rarely been reported. We hereby report the case of an 83-year-old woman who experienced non-Aspergillus ABPM with eosinophilia induced by pembrolizumab that had been prescribed for treating bladder cancer. Steroid monotherapy with prednisone was successful and pembrolizumab could be resumed. Through the present case report, we urge the clinicians to be aware of the potential risk of ABPM as a T-helper type 2-associated immune-related adverse event.</div></div>","PeriodicalId":51565,"journal":{"name":"Respiratory Medicine Case Reports","volume":"54 ","pages":"Article 102179"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Allergic bronchopulmonary mycosis induced by pembrolizumab for bladder cancer: A case report\",\"authors\":\"Hiroki Iida , Kenichiro Atsumi , Naohiro Kadoma , Sae Takashima , Yukari Shirakura , Ayana Suzuki , Kakeru Hisakane , Ryo Matsuoka , Koji Nagata , Masahiro Seike , Takashi Hirose\",\"doi\":\"10.1016/j.rmcr.2025.102179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Pembrolizumab is an immune checkpoint inhibitor (ICI) of programmed cell death-1 category, used for treating various types of cancer. ICIs can sometimes result in immune-related adverse events. Allergic bronchopulmonary mycosis (ABPM) induced by ICI has rarely been reported. We hereby report the case of an 83-year-old woman who experienced non-Aspergillus ABPM with eosinophilia induced by pembrolizumab that had been prescribed for treating bladder cancer. Steroid monotherapy with prednisone was successful and pembrolizumab could be resumed. Through the present case report, we urge the clinicians to be aware of the potential risk of ABPM as a T-helper type 2-associated immune-related adverse event.</div></div>\",\"PeriodicalId\":51565,\"journal\":{\"name\":\"Respiratory Medicine Case Reports\",\"volume\":\"54 \",\"pages\":\"Article 102179\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory Medicine Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213007125000152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213007125000152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

Pembrolizumab是一种程序性细胞死亡-1类免疫检查点抑制剂（ICI），用于治疗各种类型的癌症。ici有时会导致免疫相关的不良事件。ICI致变应性支气管肺真菌病（ABPM）报道甚少。我们在此报告一例83岁的女性，她经历了非曲霉性ABPM伴嗜酸性粒细胞增多症，而派姆单抗已被用于治疗膀胱癌。类固醇单药治疗强的松是成功的，派姆单抗可以恢复。通过本病例报告，我们敦促临床医生意识到ABPM作为t辅助型2相关免疫相关不良事件的潜在风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Allergic bronchopulmonary mycosis induced by pembrolizumab for bladder cancer: A case report

Pembrolizumab is an immune checkpoint inhibitor (ICI) of programmed cell death-1 category, used for treating various types of cancer. ICIs can sometimes result in immune-related adverse events. Allergic bronchopulmonary mycosis (ABPM) induced by ICI has rarely been reported. We hereby report the case of an 83-year-old woman who experienced non-Aspergillus ABPM with eosinophilia induced by pembrolizumab that had been prescribed for treating bladder cancer. Steroid monotherapy with prednisone was successful and pembrolizumab could be resumed. Through the present case report, we urge the clinicians to be aware of the potential risk of ABPM as a T-helper type 2-associated immune-related adverse event.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊